All In Biotech

Free tool

FAERS Monitor: Mounjaro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215866 or its brand name (Mounjaro, Tirzepatide). Reports on generic versions are filed under their own applications.

Reports

100,728

Serious

27,362

27% of reports

Hospitalization

9,837

Death reported

887

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • incorrect dose administered17,484
  • nausea10,241
  • injection site pain9,528
  • off label use8,262
  • diarrhoea6,368
  • vomiting5,525
  • extra dose administered5,273
  • constipation3,915
  • injection site haemorrhage3,644
  • product dose omission issue3,451
  • injection site erythema3,219
  • blood glucose increased3,088
  • drug ineffective2,768
  • fatigue2,759
  • decreased appetite2,531

Reports by year received

View as table
YearReports
20166
20176
20183
201924
202030
202132
20225,039
202320,764
202422,632
202531,711
202620,481

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,953,431 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
extra dose administeredSignal5,27331.130.2133,848
incorrect dose administeredSignal17,48417.217.0249,636
injection site haemorrhageSignal3,6449.99.628,042
injection site painSignal9,5286.76.545,077
injection site erythemaSignal3,2195.55.311,719
constipationSignal3,9153.83.78,008
blood glucose increasedSignal3,0883.53.35,366
nauseaSignal10,2412.72.711,461
vomitingSignal5,5252.52.44,889
product dose omission issueSignal3,4512.52.43,018
decreased appetiteSignal2,5312.32.21,837
diarrhoeaSignal6,3682.12.03,599
off label use8,2622.01.94,138
fatigue2,7590.70.7263
drug ineffective2,7680.40.42,132

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.